SCHOTT Doubles Production Capacity for Polymer Syringes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SCHOTT Doubles Production Capacity for Polymer Syringes


SCHOTT installed a new line in its St. Gallen, Switzerland facility to manufacture small-size (1 to 10 mL), ready-to-fill syringes made of cyclic olefin copolymer (COC), the company noted in a press release. This expansion doubles SCHOTT’s production capacity for COC syringes.

COC is an inert material that is compatible with a broad range of drugs. SCHOTT says its syringes have excellent barrier properties and glass-like transparency and are break-resistant and lightweight. The syringes are manufactured in cleanrooms using a fully automated process from injection molding to the final packaging. The syringes are sterilized and are ready for aseptic-filling operations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here